Post on 10-May-2015
Clinical and TranslationalScience Institute / CTSIat the University of California, San Francisco
Early Translational ResearchJuly 28, 2011
June Lee, MDDirector, Early Translational Research CTSIAssociate Professor, Department of Medicine
Prior experience
• Joined CTSI on 4/26/11
• Title: Director of Early Translational Research
• Prior experience:– 2004-2011 Genentech Inc
• Head of Infectious Diseases, Cardiovascular/ Metabolic Diseases, Respiratory Diseases in Early Clinical Development (Pre-clinical to end of Phase II)
– 1995-2004 UCSF• Pulmonary/Critical Care Faculty• Director of High Risk Asthma Clinic, SFGH• Pulmonary Critical Care Fellow/ Research Fellow
Why now?
• UCSF– Science/scientists– Intent and commitment– Leadership
• External to UCSF– Funding agencies (NIH-NCRR, NCATS)– Regulatory agencies(e.g. FDA)– Industry
Goal: Facilitate/enhance/accelerate earlytranslational research at UCSF
What I’ve been doing
• Listening tour
• Assessing current T1 activities/efforts at UCSF
• Working on a business plan
Translational research
Academia
Start up company/ biotech
Large pharma/company
Academia
Start up company/
biotechLarge
pharma/company
Early (T1) Late (T2)
Bench Bedside Community
Outcomes/ ImpactOutcomes/ Impact BetterHealth
Early translational gaps
• Science to invention
• Invention to product
• Bench to bedside
• Bedside to bench
• Community to bench/ bedside
• Academia to industry
Lead, Influence, Drive…Improve Health
T1 Translational Catalyst Award
• Identify the best projects– Diagnostics, devices, or therapeutics
• Bring in missing pieces– Panels include people from industry and
academics– Panels review and provide individualized feedback
• Leverage limited resources– Identify partnerships if appropriate
Gap: Invention to Product
Phased award approach•Attractiveness•Ease of Implementation•Intellectual Property
Gap: Invention to Product
T1 Catalyst Award program assessment
• Status– Completed 3 cycles of funding to date– Number of proposals submitted was limited– Initial target: “Invention to product” stage but
many proposals were “science to invention” stage
• Feedback– Pilot grants helped advance programs– Customized consulting service very useful
T1 translational catalyst program
Identify & Enable
ScienceInvention
InventionProduct
Gap: Science to Invention, Invention to Product
T1 Translational Award Program
• Planning for multiple tracks– Therapeutics– Diagnostics– Devices– mHealth– Orphan/ rare diseases
Innovative partnerships
• Critical to extending the T1 translational capacity in academia
• Non-traditional models and re-defining the boundaries of private/public partnerships– Pharma/academia– Early stage investors (e.g. Venture capital)– Foundations and venture philanthropy– Others
Near term focus
• Enhancing T1 translational catalyst program
• Build/enhance innovative partnerships to support T1 translational research efforts
• Continue to assess for opportunities– Multidisciplinary cross fertilization
• Bench to bedside• Bedside to bench• Community to bench/bedside
– Education (T1 focused)
• Definition of success
How you can help me
• Please let me know if what has worked well in the past at UCSF and what could work better
• If you’re aware of interesting/successful programs in early translational space, please let me know
• If you have a project/program/issue that CTSI may be able to help with, please call/contact
• Other inputs/perspectives/constructive feedback are all welcome
Accelerate research to improve health
• Identify and address gaps
• Be agile
• Take smart risks
• Collaborate
UCSF SOM/ SON/ SOD/ SOP, CTSI, QB3, NIH, NCATS, Pfizer, Sanofi, Bayer, Genentech/ Roche… many more
THANK YOU!
Questions/Comments415-514-8062
june.lee@ucsf.edu